You are here
Real-World Data Show V-Go Lowers Both A1c and Insulin Dose for Diabetes Patients
Real-world study data show that the wearable insulin delivery system V-Go (Valeritas Inc.) lowered patients’ hemoglobin A1c levels while reducing their total daily insulin doses, according to a presentation at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress in Nashville, Tennessee.
In a retrospective cohort analysis by Diabetes America of data collected from electronic records, 153 patients suboptimally controlled on their current regimen were switched to V-Go. They were either previously on multiple daily insulin injections (MDI), long-acting basal insulin therapy (Basal), or were naïve to insulin at baseline (Naïve). Follow-up data were collected for each subsequent visit where an A1c value was recorded.
Data demonstrated that all three cohorts experienced an improvement in glycemic control on V-Go. For those patients previously on insulin, the prescribed total daily dose also significantly decreased from the amount prescribed before switching to V-Go therapy.
The A1c percentage-point changes at the first and second follow-up visits (approximately three and six months) were: All patients, –1.7 and –1.8; MDI patients, –1.2 and –1.2; Basal patients, –1.9 and –2.3; and Naïve patients, –3.1 and –3.3, respectively. MDI and Basal patients experienced a 31% to 41% reduction in the total daily insulin dose administered compared to the amount prescribed at baseline.
V-Go is a wearable, basal-bolus insulin delivery system that enables diabetes patients to administer a continuous, preset basal rate of insulin over 24 hours and provides on-demand bolus dosing at mealtimes with one insulin.
Valeritas noted that the data was taken from patients in a real-world, clinical setting. Treatment followed normal clinical practice with no required physician office visits, mandated treatment protocols, or forced titration algorithms. Patients were responsible for obtaining all prescribed therapies.
The poster presentation was one of three regarding V-Go at the AACE meeting.
In the second poster, the safety and efficacy of V-Go was investigated in 21 patients with latent autoimmune diabetes in adults (LADA) or with type-1 diabetes (T1DM) with elevated blood glucose levels. All participants switched from a standard multiple daily insulin injection regimen to V-Go. Data demonstrated that these patients experienced significant A1c reductions and decreased insulin requirements.
The third poster reported and analyzed data collected from two patients, both more than 65 years old, with poorly controlled type 2 diabetes. After switching from their previous insulin regimen to V-Go, both patients experienced improved glycemic control and reduced their total daily insulin requirements.
Source: Valeritas Inc., May 15, 2015.